We are pleased to announce our participation in the upcoming seventh edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID 2023), which will be held in Lyon, France on November 22-23, 2023.
Our team at Novaxia will be joining forces with Voxcan, both part of the ERBC Group, and will be waiting for you at booth 11 to discuss how our collaboration can provide you with a one-stop shop for your non-clinical studies.
Our team Marianne Figl, PhD in virology, cellular and molecular biology, study director, infectious disease department, Voxcan, ERBC Group, Julia Matonti, Business Development Manager, Voxcan, ERBC Group, Raafat Fares, Scientific Director, ERBC Group, and Pascal Clayette, Associate Scientific Director, Immunology & Virology, ERBC Group are looking forward to meeting you and discussing our comprehensive range of preclinical services.
Our mission as a pathology hub is to enhance scientific projects with a wide range of techniques and skills. Voxcan, with 16 years of experience, is your partner for biodistribution, mechanistic and proof of concept studies based on in vitro and in vivo models combined with non-invasive high-resolution imaging in a wide range of small animal species. We cordially invite you to attend the oral presentation of their latest work on, “Recombinant multimeric spike proteins: A promising vaccine against COVID-19”, bringing hope for an adaptable vaccine against new SARS-CoV-2 strains, using rational design for broader variant coverage.
Commentaires récents